# Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

> **NCT00068250** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 60 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma

## Interventions

- **DRUG:** rituximab
- **DRUG:** methotrexate
- **DRUG:** temozolomide 100 mg/m^2
- **DRUG:** temozolomide 150 mg/m^2
- **DRUG:** temozolomide 200 mg/m^2
- **RADIATION:** radiation therapy
- **DRUG:** post-radiation therapy temozolomide

## Key facts

- **NCT ID:** NCT00068250
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068250, "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT00068250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*